Sanofi stock holds with $67 target at TD Cowen

TD Cowen reiterated a Hold rating on Sanofi (SNY) with a $67 price target, citing discussions with the company's CFO regarding product announcements, mid-term financials, and macroeconomics. Sanofi expressed confidence in meeting Dupixent guidance, expects no significant LOE impact until post-2031, and views its COVID/Flu vaccine as valuable. The company anticipates significant growth for Beyfortus, projecting peak sales of €2-3 billion despite competition in the RSV monoclonal antibody market.

Analysis

TD Cowen's maintenance of a Hold rating on Sanofi (SNY) with a $67.00 price target presents a neutral analyst view, even as InvestingPro data suggests the stock, trading at $52.89, is undervalued and boasts a "GREAT" financial health score of 3.09. Sanofi's management, following a meeting with its CFO, projects confidence, particularly regarding its leading product Dupixent, for which guidance is expected to be met, competition is not an immediate concern, and significant loss of exclusivity (LOE) impact is not anticipated until post-2031. The company also reported positive surprise from its Covid vaccine Biologics License Application (BLA) approval and considers its COVID/Flu combination vaccine a valuable asset. Significant growth is anticipated for Beyfortus, its RSV monoclonal antibody, with peak sales projected between €2 billion and just under €3 billion in the near term and an expectation that RSV monoclonal antibodies could capture up to 80% of the market at their peak, with substantial growth forecast for 2025-26. These product-specific outlooks, alongside Sanofi's mid-term financial projections and navigation of macroeconomic factors like tariffs and the Multifiber Arrangement, underpin the company's current market capitalization of $128.8 billion on $48.9 billion in annual revenue.

Key Decisions for Investors

• Investors should monitor Sanofi's execution on Dupixent's continued growth and Beyfortus's market penetration against its optimistic peak sales and market share projections, as these are pivotal to achieving its mid-term financial targets.
• Upcoming product pipeline announcements, particularly concerning the COVID/Flu combination vaccine, should be watched for potential catalysts that could influence the stock's valuation beyond the current Hold rating.
• Given Sanofi's strong financial health, confidence in key franchises, and InvestingPro's undervaluation signal, investors may find value in further scrutinizing the disconnect with the neutral analyst rating, particularly if current growth drivers perform as projected.